Mercodia is a world-leading developer, manufacturer and provider of high quality immunoassay kits. With the stringent quality system inherited from Pharmacia Diagnostics, the initial business concept of Mercodia was to develop robust and accurate ELISA assays for use in human diagnostics. The increased demand from pharmaceutical and academic research for reliable assays that ensure reproducible results created an interest from researchers around the world for Mercodia’s products and services.
Mercodia specializes in ELISA assays for clinical as well as research applications, notably within diabetes, obesity and cardiovascular disease. Assays applicable in both human and animal models are offered.
Mercodia supplies products and services to all major international markets from its facilities in Uppsala, Sweden. More than ninety percent of our production is exported to approximately 100 countries worldwide.
The US subsidiary, Mercodia Inc, is based in Winston Salem, North Carolina and is involved in direct sales, distribution and support to North American customers. Mercodia provides a professional support system by collaborating with worldwide customers and institutions to develop new applications for existing products and new diagnostics for emerging markets.
Mercodia is the preferred choice of leading researchers around the world.
- Immunoassays for validation of diabetes biomarkers
Making the right interpretation of biomarker data relies on the expertise of the scientist and the quality of the measurement methods. Well-established reagents are key to achieving assay robustness, specificity and sensitivity.
During the 2019 AAPS PharmSci 360, Hanna Ritzén, Managing Director R&D at Mercodia, will present Risk assessment, definition, characterization and control of critical reagents in biomarker assays in Classroom 5, Hall 234 on Tuesday (Nov 5th) at noon. Take the opportunity to learn more about critical reagents and the benefits of reagent characterization and control for your bioanalytical strategy.
Hanna Ritzén has worked with LBAs and critical reagents in a regulated setting for more than 15 years, and she will provide real-world examples of controlling reagents in problem-solving and managing lot-to-lot consistency strategies. How do we define critical reagents? Can we generalize? Why do we need to spend time on reagent characterization? How do we know that our control is enough? What do we do when we meet the unexpected?
After the presentation you are invited to our Partner Reception, giving you an opportunity to mingle with peers and discuss further with Hanna Ritzén and other Mercodia representatives.
See you in Classroom 5, Hall 234 on Nov 5th at noon!
Carissa Jones, President at Mercodia Inc
- Mercodia launches new product
- Panel discussion: considerations and challenges of ligand binding assays